Company Profiles

driven by the PitchBook Platform

Artielle ImmunoTherapeutics

Artielle ImmunoTherapeutics
2004 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Conv. Debt LATEST DEAL TYPE
$285k LATEST DEAL AMOUNT
$15.7M TOTAL AMOUNT RAISED
Description

Provider of first-in-class platform of biologic drugs designed to treat degenerative diseases. The company's biologic drugs targets the CD74 receptor on monocytes and blocks the action of macro-phage migration inhibitory factor (MIF), enabling healthcare industry to treat neuroinflammatory and degenerative diseases including multiple sclerosis (MS), optic neuritis, methamphetamine addiction and stroke.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
400 South El Camino Real
Suite 1200
San Mateo, CA 94402
United States

+1 (650) 401-2000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Artielle ImmunoTherapeutics’s full profile, request a free trial.

Artielle ImmunoTherapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Convertible Debt 07-Sep-2010 $285k $15.7M Completed Generating Revenue
6. Convertible Debt 30-Sep-2009 00000 000.00 Completed Startup
5. Convertible Debt 23-Jan-2009 00.000 000.00 Completed Startup
4. Convertible Debt 08-May-2008 000 000.00 Completed Startup
3. Convertible Debt 14-Dec-2007 000 000.00 Completed Startup
2. Convertible Debt 20-Jun-2007 $4.1M $8.1M Completed Startup
1. Early Stage VC (Series A) 28-Jun-2004 $4M $4M Completed Clinical Trials - Phase 1
To view this company’s complete deal history including valuation and funding request access »

Artielle ImmunoTherapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Northwest Technology Ventures Venture Capital Minority 000 0000 000000 0
Pelion Venture Partners Venture Capital Minority 000 0000 000000 0
Reference Capital Management Venture Capital Minority 000 0000 000000 0
Sanderling Ventures Venture Capital Minority 000 0000 000000 0
Tenex Greenhouse Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Artielle ImmunoTherapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Gilbert Miller Director & Secretary
Peter McWilliams Ph.D Chairman & Acting Chief Executive Officer
John Metcalf Ph.D Director
Shahab Fatheazam Director

Artielle ImmunoTherapeutics Board Members (1)

Name Representing Role Since Contact
Info
Peter McWilliams Ph.D Self Chairman & Acting Chief Executive Officer 000 0000